Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Grand Mal Seizure Market size was over USD 2.4 billion in 2024 and is estimated to reach USD 4 billion by the end of 2037, expanding at a CAGR of 4.5% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of grand mal seizure is evaluated at USD 2.5 billion.
As per a report published in 2024 by the Health and Global Policy Institute, more than 50 million people are affected with epilepsy which causes seizures. It has been identified as one of the most usual neurological disorders that are caused by unchecked electrical activities. Additionally, the approximate prevalence rate of epilepsy ranges between 0.5% to 1% globally and is considered to be congenital among children. Besides, epilepsy-based seizures are connected with brain tumors, stroke, and Alzheimer’s disease, which is extremely prevalent among the elderly population above 65 years of age. All these factors are projected to highly impact the evolution of the grand mal seizure market during the forecast period.
Grand mal seizure comprises of two phases- tonic and clonic. As per the Mayo Clinic Organization, the tonic phase results in the absence of consciousness wherein there is sudden muscle contraction that lasts up to 10 to 20 seconds. On the other hand, the clonic phase leads to rhythmic contraction of muscles that is evident between 1 to 2 minutes. Besides, improper formation of blood vessels in the brain and genetic syndromes are developmental factors associated with this type of seizure. Hence, dietary therapy, nerve stimulation, surgery, and standard medication are essential to overcome seizures. All these components are being highly driven to stimulate and boost the grand mal seizure market.
Grand Mal Seizure Sector: Growth Drivers and Challenges
Growth Drivers
- Development of neuromodulation surgeries: According to the American Association of Neurological Surgeons 2024, deep brain stimulation (DBS), responsive neurostimulation (RNS), and vagal nerve stimulation (VNS) are the latest surgical procedures to aid patients with epilepsy. Out of these, RNS ensures the placement of dual electrodes on the brain surface which has more exposure to seizure occurrence. This records the brain waves and the data gathered by the neurostimulator is secured in a web-based application for future accessibility. As per a report published in October 2022 by NLM, the responsive rate of this surgery ranges between 44% to 61% depending upon the age, thus positively driving the grand mal seizure market growth.
- Expansion in digital health services: Accurate seizure-detecting digital solutions provide data on the frequency tailored by features. In August 2023, NLM published an article based on a survey conducted on 115 participants regarding their interest in the use of the MOND application as a telehealth service to aid seizure. The function of the application was highly supported by participants denoting the display of body parameters, schedule and module of medication, regular documentation pertaining to side effects and change in drug intake, sharing medical information, electronic communication, and emergency management. Thereby, telemedical service is effectively uplifting the grand mal seizure market.
Challenges
- Limited awareness of epilepsy: Despite the evolution of modern treatment and healthcare services, the social stigma associated with grand mal seizure still prevails, especially in developing nations. Lack of recognition and cultural misconceptions are the main factors that result in delayed diagnosis of seizures. Additionally, communal isolation is familiar among adults with epilepsy and it is associated with inadequate lifestyle and depression. It is also a risk factor that leads to poor well-being, reduced cognition, and mortality among the general population, thus restraining market development.
- Unknown action mechanism: There are specific drug applications for which the mode of action remains unknown. For instance, adrenocorticotrophin (ACTH) is a type of medicine that is useful to combat seizures. But it remains unknown in terms of Synacthen as to what particular seizure it caters to. Likewise, nitrazepam, paraldehyde, phenobarbitone, potassium bromide, stiripentol, and sulthiame are other medicines that do not comprise any particular measurement to aid seizures, thus a restraining aspect for the grand mal seizure market.
Grand Mal Seizure Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.5% |
|
Base Year Market Size (2024) |
USD 2.4 billion |
|
Forecast Year Market Size (2037) |
USD 4 billion |
|
Regional Scope |
|
Grand Mal Seizure Segmentation
By Diagnosis (Electroencephalogram, Magnetic Resonance Imaging, Computed Tomography, Blood Tests, Neurological Exam, Others)
Based on diagnosis, the electroencephalogram (EEG) segment is projected to hold grand mal seizure market share of more than 36.7% by 2037. It is an effective diagnostic tool to examine patients with familiar seizures based on which appropriate therapy is provided. In a population-based study conducted by Epilepsy & Behaviour in January 2025, 7.7% out of 520 patients displayed epileptiform pursuit and 29% exhibited pathological slowing on their respective EEG. Additionally, the seizure re-occurrence was depicted at 33.7% and the epileptic-based activity anticipated seizure with a recurrence risk of 82.5%, thus thriving the growing demand for the diagnosis.
By Treatment (Antiepileptic Drugs, Surgery, Dietary Therapy, Supportive Care)
The antiepileptic drugs segment is anticipated to dominate the grand mal seizure market during the forecast period at a considerable rate. These drugs are useful in controlling seizures approximately in 7 out of 10 people, as stated in the NHS 2023 report. Additionally, these alter the electrical flow and initiate chemical transmission in and around neurons in the cell membrane and synapes. Thereby, this particular treatment reduces the enhancing and excitation inhibition, thus positively impacting the growth of the grand mal seizure market.
List of antiepileptic medication for seizure disorders
|
Generic Name |
Trade Name |
Seizure type |
|
Acetazolamide |
Diamox |
Seizure-based glaucoma |
|
Clobazam |
Frisium |
Control seizures in patients with Lennox-Gastaut syndrome |
|
Diazepam |
Valium |
Control and relief of anxiety due to agitation |
|
Ethosuximide |
Zarontin |
Reduce petit mal seizure |
|
Gabapentin |
Neurontin |
Ensure absence of epilesptic seizure |
Source: The Royal Children’s Hospital Melbourne 2025
Our in-depth analysis of the global market includes the following segments:
|
By Diagnosis |
|
|
By Treatment |
|
|
By End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportGrand Mal Seizure Industry - Regional Synopsis
North America Market Analysis
North America grand mal seizure market is projected to dominate revenue share of over 30% by 2037. Huge expenditure on healthcare services and substantial adoption of medical remedies are essential factors driving the market exposure within the region. According to the European Journal of Epilepsy 2024, North America comprises 23 anti-seizure drugs that have been approved by the U.S. FDA which further incorporated 223 oral formations comprising 111 generics and 112 brand names as of 2023. The standard price index of branded anti-seizure drugs ranged from USD 8.71 to USD 15.43 and generic ones ranged between USD 1.39 to USD 1.26.
The U.S. grand mal seizure market is booming owing to the prevalence of the disease among 25% of the population. Additionally, 11% of the population suffer from seizures at any point in their life, followed by 3% diagnosed with epilepsy, and 1% cater to emergency hospitalization in the region. According to the American Epilepsy Society 2024, there are certain anti-seizure drugs that provide ailment to seizure within the region, including BRV, CBD, and more.
The grand mal seizure market in Canada is witnessing significant growth since seizures are quite common within the region. As reported by the Government of Canada 2024, epilepsy is the ultimate disorder leading to seizures and the frequency range between 1 every year to a handful every day. Additionally, the epilepsy occurrences are equivalent in both males and females and only differ in terms of age.
Grand mal seizure rates by age
|
Category of People |
Age |
|
13% of youth and children |
1 to 19 years |
|
63% of adults |
20 to 64 years |
|
24% of old adults |
Over 65 years |
Source: Government of Canada 2024
Moreover, the incidence of epilepsy-causing seizures witnessed the latest cases in Canada. The Government of Canada 2024 report stated that there are 66 cases of seizures among the youth-based generation, followed by 51 cases for the adults, and 87 cases for the elderly population. Hence, the growth in the number of seizure cases is highly uplifting the market.
APAC Market Analysis
The grand mal seizure market in APAC is gaining the utmost exposure and is projected to witness the fastest growth during the estimated timeline. As per a report published in October 2023 by BMC, the Asia Pacific region comprises more than 4 billion that is, 50% of the global population, out of which 23 million suffer from epilepsy. Despite the adoption of innovative ailments, nearly 90% of patients do not have access to standard healthcare services due to limited resources. According to the OECD report 2024, focus on supply chain management, informed policies, long-term recovery services, and innovative health systems are aiming to ensure future development in the region.
The grand mal seizure market in India is expecting substantial growth due to the increase in the number of disorders that result in the occurrence of seizures. Health challenges such as brain tumors, metabolic-based diseases, cerebral infections, congenital situations along with chronic drug and alcohol use prompt the occurrence of epileptic-based seizures. As depicted by Pace Hospitals, the gross presence of epilepsy in India ranges between 5.59-10 per 1000 and more than 10 million patients suffering from epilepsy constitute over 1% of the regional population. Treatment solutions to combat this include neuroimaging, cerebrospinal fluid-based tests to identify brain infections, and the adoption of a ketogenic diet is recommended to combat seizures.
The grand mal seizure market in China is growing owing to the development of treatments to aid the occurrence of seizures. In rural China, 63% of patients with seizures are devoid of receiving treatment with suitable anti-seizure drugs. Additionally, the outrage is excessive in the rural part (4.6/1,000) in comparison to coastal regions (2.4/1000). To overcome this, the Global Campaign Against Epilepsy extended support in China to implement phenobarbital (PB) as a reliable, potent, and affordable treatment choice. This drug has long-term productiveness, especially for working patients residing in the rural northeast part of the country.
Companies Dominating the Grand Mal Seizure Landscape
- UCB Pharma
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Zydus Cadila
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Johnson & Johnson
- Sun Pharmaceutical Industries Ltd.
Companies dominating the grand mal seizure market are rapidly gaining exposure as a result of the development of medicated drugs and their approval by governmental agencies. For instance, in November 2022, Nippon Shinyaku Co., Ltd. stated the launch of Fintepla Oral Solution 2.2 mg/mL for aiding patients with syndromes leading to grand mal seizure. This is even approved in Europe and the U.S. for diagnosing rare diseases resulting in seizure conditions. Thereby, contributions made by key players are positively impacting the grand mal seizure market growth.
In the News
- In July 2024, Glenmark Pharmaceuticals Ltd. received the U.S. FDA approval for Topiramate Capsules USP, 15 mg and 25 mg to stabilize the electrical activity in the brain to prevent the occurrence of seizures.
- In November 2022, Xenon Pharmaceuticals Inc. declared the launch of XEN1101 Phase 3 program and later in October 2023, approached NYU Langone Hospitals to initiate an investigational study to provide relief to patients with focal epilepsy.
Author Credits: Radhika Pawar
- Report ID: 7092
- Published Date: Feb 05, 2025
- Report Format: PDF, PPT
